Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The aim of this study was to investigate the efficacy and safety of intraperitoneal catumaxomab in heavily pretreated patients with chemotherapy-refractory ovarian cancer and recurrent symptomatic malignant ascites.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int. J. Gynecol. Cancer

Title: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

ISSN (Electronic): 1525-1438

ISSN (Print): 1048-891X

Publication date (Electronic): Nov 2014

Volume: 24

Issue: 9

Affiliations

[1 ] *Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA; †Magee Women's Hospital of UPMC, Pittsburgh, PA; ‡James Graham Brown Cancer Center, Louisville, KY; §Dartmouth-Hitchcock Medical Center, Lebanon, NH; ∥Columbia University Cancer Center, New York, NY; ¶WFU Baptist Medical Center, Winston-Salem, NC; #Barbara Ann Karmanos Cancer Center, Wayne State University, Detroit, MI; **Huntsman Cancer Institute, Salt Lake City, UT; ††Florida Hospital Cancer Institute, Orlando, FL; ‡‡Northern Indiana Cancer Research Consortium, South Bend, IN; §§University of California, San Diego, CA; ∥∥University of Oklahoma Health Science Center, Oklahoma City, OK; ¶¶Neovii Biotech GmbH (formerly Fresenius Biotech GmbH), Munich, Germany; ##Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, MA.

Article

DOI: 10.1097/IGC.0000000000000286

PubMed ID: 25254563

SO-VID: 60b53fe4-5833-487d-9b88-2372ca81a551

History

Data availability:

Comments

Comment on this article

scite_

Cited by 15

See all cited by